Latest Update on Appendix 1 of the Nitrosamine Guidelines
Latest Update on Appendix 1 of the Nitrosamine Guidelines
Tuesday, 14 May 2024
Pablo Palomar, Senior Toxicology Officer at QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
Play
Latest Update on Appendix 1 of the Nitrosamine Guidelines
AI-generated audio
2:20
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1 (EMA/154403/2024 /Rev. 4) of the Nitrosamines Guideline. In this Appendix the different nitrosamines that have an established Acceptable Intake (AI) are listed.
What’s new?
In this update, new nitrosamine drug substance-related impurities (NDSRIs) of high concern, such as N-nitroso-N-ethyl-benzylamine (NBEA), N-nitroso-desmethyl-edoxaban and N-nitroso-trientine Impurity 1, have been published. As well as other NDSRIs related to the manufacturing process of various medicines (Opipramol, Omecamtiv mecarbil, Mirabegron, Articaine, Fenfluramine, Dextromethorphan, Posaconazole, Rivaroxaban and Vibegron).
In addition, the AI value for N-nitroso-Lisinopril has been updated. It’s no longer considered a mutagenic impurity, and can therefore be controlled according to ICH Q3B.
What does this mean to you?
In recent years, significant concern has arisen due to the well-known carcinogenic potency of nitrosamine impurities. Consequently, regulatory agencies have reiterated the need for continuous review of Nitrosamine Risk Assessments. Therefore, when updates like this are published, it’s essential to pause and ensure that your reports comply with current regulations and that all potential risk factors have been accurately assessed.
This update particularly impacts medicines containing any of the active substances listed above in their formulation. If this applies to you, the first question to ask is, “Have I assessed the possible presence of these new NDRSIs?” If the answer is “no,” it’s crucial to promptly review your NRA, as there may be new risks that weren’t considered previously.
If you have already assessed these NDRSIs and identified a risk, your next step is to check whether the AI value used for calculating the acceptable limits has changed with this update. The limits may have changed significantly, potentially altering the conclusions of your confirmatory analysis results.
How can QbD Group assist you regarding this update?
Our expert team toxicologists and organic chemists is here to guide you through regulatory changes and ensure your Nitrosamine Risk Assessments are up-to-date and compliant.
Discover more expert content
Previous
Toxicology
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Toxicology
13 Aug 2025
ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation
This milestone represents a decisive step toward harmonizing international requirements for the...
Toxicology
4 Dec 2025
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
What's new? This update introduces the Acceptable Intake (AI) values for new nitrosamine drug...
Toxicology
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Toxicology
18 Sep 2024
The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs
What’s new?
Toxicology
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Toxicology
13 Aug 2025
ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation
This milestone represents a decisive step toward harmonizing international requirements for the...
Toxicology
4 Dec 2025
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
What's new? This update introduces the Acceptable Intake (AI) values for new nitrosamine drug...
Toxicology
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Toxicology
18 Sep 2024
The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs
What’s new?
Toxicology
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Toxicology
13 Aug 2025
ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation
This milestone represents a decisive step toward harmonizing international requirements for the...
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe